Literature DB >> 7475051

Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents.

B Fermini1, N K Jurkiewicz, B Jow, P J Guinosso, E P Baskin, J J Lynch, J J Salata.   

Abstract

We studied the effects of NE-10064 (azimilide), a new antiarrhythmic agent reported to be a selective blocker of the slowly activating component of the delayed rectifier, IKs. In ferret papillary muscles, NE-10064 increased effective refractory period (ERP) and decreased isometric twitch tension in a concentration-dependent manner (0.3-30 microM). Increases in ERP showed reverse use-dependence, and were greater at 1 than at 3 Hz. In contrast, changes in tension were use dependent, with larger decreases observed at 3 than at 1 Hz. In guinea pig ventricular myocytes, NE-10064 (0.3-3 microM) significantly prolonged action potential duration (APD) at 1 Hz. At 3 Hz, NE-10064 (0.3-1 microM) increased APD only slightly, and at 10 microM decreased APD and the plateau potential. NE-10064 potently blocked the rapidly activating component of the delayed rectifier, IKr (IC50 0.4 microM), and inhibited IKs (IC50 3 microM) with nearly 10-fold less potency. NE-10064 (10 microM) did not block the inward rectifier potassium current (IKl). NE-10064 (10 microM) blocked the L-type calcium current (ICa) in a use-dependent manner; block was greater at 3 than at 1 Hz. We conclude that (a) NE-10064's block of potassium currents is relatively selective for IKr over IKs, (b) NE-10064 inhibits ICa in a use-dependent fashion, and (c) NE-10064's effects on ERP and tension in papillary muscle as well as APD and action potential plateau level in myocytes may be explained by its potassium and calcium channel blocking properties.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475051     DOI: 10.1097/00005344-199508000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte.

Authors:  W C Claycomb; N A Lanson; B S Stallworth; D B Egeland; J B Delcarpio; A Bahinski; N J Izzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

2.  Inhibition of IKs in guinea pig cardiac myocytes and guinea pig IsK channels by the chromanol 293B.

Authors:  A E Busch; H Suessbrich; S Waldegger; E Sailer; R Greger; H Lang; F Lang; K J Gibson; J G Maylie
Journal:  Pflugers Arch       Date:  1996-10       Impact factor: 3.657

3.  Azimilide.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 4.  What niche will newer class III antiarrhythmic drugs occupy?

Authors:  B N Singh; J S Sarma
Journal:  Curr Cardiol Rep       Date:  2001-07       Impact factor: 2.931

5.  Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation.

Authors:  X Q Qi; D Newman; P Dorian
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

6.  Blockade of IKs by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles.

Authors:  Petsy Pui-Sze So; Xu-Dong Hu; Peter H Backx; José Luis Puglisi; Paul Dorian
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

Review 7.  A benefit-risk assessment of class III antiarrhythmic agents.

Authors:  Bente Brendorp; Oledyg Pedersen; Christian Torp-Pedersen; Naji Sahebzadah; Lars Køber
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Rabbit ventricular myocardium undergoing simulated ischemia and reperfusion in a double compartment tissue bath: a model to investigate both antiarrhythmic and arrhythmogenic likelihood.

Authors:  Joachim Alexandre; Michele Schiariti; René Rouet; Paolo Emilio Puddu
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-03-08

Review 9.  In vitro models of proarrhythmia.

Authors:  C L Lawrence; C E Pollard; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

Review 10.  New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.

Authors:  Stanley Nattel; Paul Khairy; Denis Roy; Bernard Thibault; Peter Guerra; Mario Talajic; Marc Dubuc
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.